Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Biomaterials. 2011 Jul 31;32(31):8029–8039. doi: 10.1016/j.biomaterials.2011.07.021

Figure 3. In vitro anti-leishmanial activity.

Figure 3

Anti-leishmanial activity of AmB-PMA (▲; ED50 = 0.07 ± 0.1 μg of AmB/ml) as compared to deoxycholate AmB (○; ED50 = 0.22 ± 0.1 μg AmB/ml) and liposomal AmB (□; ED50 = 0.11 ± 0.1 μg AmB/ml) in L. donovani amastigote infected macrophages (n = 9). PMA had no anti-leishmanial activity.